Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review by Bramlage, Peter & Hasford, Joerg
Cardiovascular Diabetology
Review
Blood pressure reduction, persistence and costs in the evaluation of
antihypertensive drug treatment – ar e v i e w
Peter Bramlage*
1 and Joerg Hasford
2
Address:
1Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow, Germany and
2Institut für Medizinische
Informationsverarbeitung, Biometrie und Epidemiologie, University of München, Munich, Germany
E-mail: Peter Bramlage* - peter.bramlage@gmx.de; Joerg Hasford - has@ibe.med.uni-muenchen.de
*Corresponding author
Published: 27 March 2009 Received: 9 March 2009
Cardiovascular Diabetology 2009, 8:18 doi: 10.1186/1475-2840-8-18 Accepted: 27 March 2009
This article is available from: http://www.cardiab.com/content/8/1/18
© 2009 Bramlage and Hasford; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background: Blood pressure lowering drugs are usually evaluated in short term trials
determining the absolute blood pressure reduction during trough and the duration of the
antihypertensive effect after single or multiple dosing. A lack of persistence with treatment has
however been shown to be linked to a worse cardiovascular prognosis. This review explores the
blood pressure reduction and persistence with treatment of antihypertensive drugs and the cost
consequences of poor persistence with pharmaceutical interventions in arterial hypertension.
Methods: We have searched the literature for data on blood pressure lowering effects of
different antihypertensive drug classes and agents, on persistence with treatment, and on related
costs. Persistence was measured as patients' medication possession rate. Results are presented in
the form of a systematic review.
Results: Angiotensin II receptor blocker (ARBs) have a competitive blood pressure lowering
efficacy compared with ACE-inhibitors (ACEi) and calcium channel blockers (CCBs), beta-blockers
(BBs) and diuretics. 8 studies describing the persistence with treatment were identified. Patients
were more persistent on ARBs than on ACEi and CCBs, BBs and diuretics. Thus the product of
b l o o dp r e s s u r el o w e r i n ga n dp e r s i s t e n c ew a sh i g h e ro nA R B st h a no na n yo t h e rd r u gc l a s s .
Although the price per tablet of more recently developed drugs (ACEi, ARBs) is higher than that of
older ones (diuretics and BBs), the newer drugs result in a more favourable cost to effect ratio
when direct drug costs and indirect costs are also considered.
Conclusion: To evaluate drugs for the treatment of hypertension several key variables including
the blood pressure lowering effect, side effects, compliance/persistence with treatment, as well as
drug costs and direct and indirect costs of medical care have to be considered. ARBs, while
nominally more expensive when drug costs are considered only, provide substantial cost savings
and may prevent cardiovascular morbidity and mortality based on the more complete
antihypertensive coverage. This makes ARBs an attractive choice for long term treatment of
hypertension.
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Blood pressure lowering drugs are approved based on
short term trials determining the absolute blood pressure
reduction during trough and the duration of the
antihypertensive effect after single or multiple dosing.
The absolute amount of blood pressure reduction in
mmHg over the short term can however not be
extrapolated to the degree of protection against hyper-
tensive end organ damage because low patient's com-
pliance and poor persistence with treatment may lead to
early discontinuation of treatment in clinical practice
[1-3].
To be effective treatment must continue, sometimes for a
patient's life, despite an absence of symptoms or any
perceived benefit to the patient [4-6]. Unfortunately, lack
of symptoms in hypertension together with a low
tolerability of some antihypertensive drugs are some of
the most common reasons for patients discontinuing
treatment or not taking the medication at the prescribed
dose and at the required intervals. A poor compliance/
persistence in turn, leads to an increase in the use of
healthcare resources and an increase in overall expendi-
ture [7]. Thus, poor persistence has been recognised as a
serious problem with significant economic conse-
quences. Although studies have investigated the extent
of the economic effect of non-compliance, such studies
evaluated different aspects of this effect and are not able
to give a complete picture.
Therefore this review explores the cost consequences of
poor persistence with pharmaceutical interventions in
arterial hypertension. The aim is 1) evaluating the
antihypertensive effects of drugs, 2) reviewing persis-
tence with different pharmacotherapies and 3) exploring
the related expenditure, such as drug costs, overall
healthcare expenditure and productivity costs, and
investigating the effect it has on the cost-effectiveness
of pharmaceutical interventions for hypertension.
Materials and methods
Definitions
In this review, the definitions of the International Society
for Pharmacoeconomics and Outcomes Research
(ISPOR) were used, which define compliance as taking
medication as prescribed, on time and at the correct
dose, and persistence as the continuing use in time of the
prescribed therapy [8]. Defined daily doses (DDDs)
based on the assumed average maintenance dose per day
were used to compare costs.
Searches
We have identified studies describing compliance/persis-
tence with treatment using different antihypertensive
classes and their related costs. The following search term
was entered into pubmed: "hypertens* AND (complia*
OR adhere* OR persiste*) AND (cost* OR econo*)" with
the limits: "Publication Date from 1995/01/01, Humans,
English." A manual search of the reference lists from
retrieved publications was also performed to identify
further relevant studies.
Selection criteria
Studies were regarded relevant if they were in English
language, involved human studies published before
November 2008, involved patients with hypertension,
examined compliance (adherence) and/or persistence to
pharmaceutical interventions (even if the primary
objective was not to measure compliance/persistence),
provided an economic evaluation or cost analysis and
quantified the cost consequences of compliance/persis-
tence. Studies published before 1995 were excluded as
results from those earlier studies could not be compared
with those from more recent studies because of changes
in treatment patterns, study methodology and the price
of healthcare resources, including drug prices. Studies
were also excluded from analysis if the economic
consequence of compliance/persistence was not quanti-
fied.
Data extraction
Qualitative data extracted from the studies included the
country where the study was performed, the number of
patients, the database used, the type of study (retro-
spective, prospective, model or based on assumptions),
the duration of follow-up, definitions used for persis-
tence, compliance, switching and discontinuation as well
as the type of patients with mean age, gender and drugs
a tt h eo n s e to ft h es t u d y( s e eT a b l e1 a& 1 b ) .
Studies on the antihypertensive effect of drugs
As the number of studies well exceeded the handling
limit and an excellent meta-analysis on the blood
pressure lowering effect of antihypertensive drugs was
available, we referred to the work of Law and colleagues
[9], who analyzed the data from 354 randomized,
placebo controlled studies. 39,879 patients in all trials
received active treatment and 15,817 received matching
placebo. Active treatment options investigated were
angiotensin II receptor blockers (ARBs), ACE-inhibitors
(ACEi), calcium channel blockers (CCBs), beta-blockers
(BBs) and diuretics. The pre-treatment blood pressure
(mmHg) was 154 (90%CI 139 to 170)/97 (87 to 106) in
both the treatment and placebo group. The median
duration of the trials was 4 weeks (90%CI 2–12).
Results are summarized in Table 2, illustrating a
strong reduction of systolic blood pressure with ARBs
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a – Studies on compliance/persistence with treatment (Part 1)
References Database Study design Definitions Patients Baseline
Bloom 1998 [15]
USA
21,723 pts.
Bloom cohort study,
longitudinal database
with pharmacy
administrative claims
[15]
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Persistence: at least 3
refills over 1 year
Switch: no initial AH
drug but other AH
Discontinued: ≤ 2
refills
Patients with initiation
on antihypertensive
monotherapy, and no
treatment within the
12 month before
Mean age: 56 y
Male: 44.1%
Initial drug class:
ARBs: 2.6%
ACEi: 26.9%
CCBs: 23.4%
BBs: 23.0%
Diuretics: 24.1%
Rizzo 1996 [27]
USA
Pts. not available
National Medical
Expenditure Survey
1987
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
not available Patients with chronic
illnesses including
hypertension
Age range 18–64 y
Rizzo 1997 [25]
USA
7,211 pts.
Pennsylvania Medicaid
Management
Information System
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Compliance: estimated Patients with a
treatment for
hypertension
(monotherapy)
Mean age: 59.4 y
Male: 29%
Initial drug class:
ACEi: 32%
CCBs: 49%
BBs: 11%
Diuretics: 8%
Hughes 1998 [26]
UK
7,741 pts.
MEDIPLUS database Retrospective,
longitudinal cohort
study
26 months follow-up
Persistence: patients
continuing therapy at 6
months
Patients with new
antihypertensive
treatment
Not available
Conlin 2001 [18]
USA
15,175 pts.
Bloom cohort study,
longitudinal database
with pharmacy
administrative claims
[15]
Retrospective,
longitudinal cohort
study
1+3y e a rf o l l o w - u p
Persistence: at least 3
refills over 1 year
Switch: no initial AH
drug but other AH
Discontinued: ≤ 2
refills
Patients with initiation
on antihypertensive
monotherapy, and no
treatment within the
12 month before
Mean age: 56 y
Male: 45%
Initial drug class:
ARBs: 3.0%
ACEi: 29.2%
CCBs: 25.6%
BBs: 25.1%
Diuretics: 17.1%
Hasford 2002 [36]
Germany, France,
UK
2,416 pts.
IMS MediPlus Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Persistence: 4 refills
over 1 year
Switch: no initial AH
drug but other AH
Discontinued: stopped
refill for at least 30
days after medication
ran out
Patients with initiation
on antihypertensive
monotherapy, no
previous treatment
Mean age: 61
Male: ~50%
Initial drug class:
ARBs: 31.2%
ACEi: 13.8%
CCBs: 19.3%
BBs: 18.3%
Diuretics: 17.5%
Degli Esposti 2001
Italy
4,614 pts.
Local Health Unit of
Ravenna
Retrospective,
longitudinal cohort
study
Patients with a first
prescription for
amlodipine, atenolol
fosinopril, indapamide
or losartan
Degli Esposti 2002
[22]
Italy
7,312 pts.
Local Health Unit of
Ravenna
Retrospective,
longitudinal cohort
study
3y e a rf o l l o w - u p
Continuers
(persistence): at least 2
prescriptions per year
over 3 years
Discontinuers: at least
2 prescriptions per
year for the first year
only or and the second
year but not in the
third year
Patients with new
antihypertensive drug
treatment
Mean age: ~63 y
Male: 43.1
Initial drug class:
ARBs: 2.7%
ACEi: 33.1%
CCBs: 25.7%
BBs: 15.9%
Diuretics: 22.6%
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b – Studies on compliance/persistence with treatment (Part 2)
References Database Study design Definitions Patients Baseline
Degli Esposti 2004
[23]
Italy
14,062 pts.
Local Health Unit of
Ravenna
Prospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Persistence: therapy
duration of > 273 days.
Patients with new
antihypertensive drug
treatment
Mean age: 56.9 y
Male: 43.4%
Initial drug class:
ARBs: 6.9%
ACEi: 28.0%
CCBs: 23.8%
BBs: 17.6%
Diuretics: 23.8%
Erkens 2005 [37]
Netherlands
2,243 pts.
PHARMO database
including pharmacy
records and
hospitalisation
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Persistence: drugs for
at least 270 d and 3
month after the 1 year
follow-up
Switch: no initial AH
drug but other AH
Discontinued: stopped
refill for at least 30
days after medication
ran out
Patients with initiation
on antihypertensive
monotherapy, no
previous treatment
Mean age: most pts.
(42.6%) 40–59 y
Male: 43.1%
Initial drug class:
ARBs: 19.9%
ACEi: 18.4%
CCBs: 20.3%
BBs: 21.0%
Diuretics: 20.4%
Sokol
2005 [24]
USA
7,981 pts.
Participants of a
medical and drug
benefit plan sponsored
by a large
manufacturing
employer
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Adherence was
defined as the
percentage of days
during the analysis
period that patients
had a supply of 1o r
more maintenance
medications for the
condition (based on
"days' supply" data in
patients' prescription
claim records).
Patients being on the
respective treatment
for at least 12 months.
Mean age: 54.2 y
Male: 53.3%
Veronesi
2007 [19]
Italy
347 pts.
Outpatients of a
hypertension clinic
Prospective,
longitudinal, single-
blind, cohort study
2y e a rf o l l o w - u p
Persistence: continued
use of the initial AH
over time
Patients with initiation
on antihypertensive
monotherapy, no
antihypertensive
treatment in the last 6
month
Mean age: 59.4 y
Male: 59.4%
Initial drug class:
ARBs: 15.2%
ACEi: 17.5%
CCBs: 18.1%
BBs: 17.5%
Diuretics: 18.1%
Hasford 2007 [17]
Germany
13,763 pts.
IMS disease analyse
database
Retrospective,
longitudinal cohort
study
3y e a rf o l l o w - u p
Persistence: continued
treatment over time
Discontinuation: no
repeat AH drug
prescription for more
than 6 month
Patients with initiation
on antihypertensive
monotherapy or a
specified combination,
no antihypertensive
treatment in the last 6
month
Median age: 65 y
Male: 44.2%
Initial drug class:
ARBs: 5.4%
ACEi: 21.0%
CCBs: 11.8%
BBs: 37.3%
Diuretics: 14.5%
Patel
2007 [16]
USA
242,882 pts.
Administrative
pharmacy claims from
MedImpact
Retrospective,
longitudinal cohort
study
1y e a rf o l l o w - u p
Persistence: continued
treatment over time
Discontinuation: no
refill for 60 days after
running out of pills
Patients with initiation
on antihypertensive
monotherapy
Median age: 54.5 y
Male: 43.1%
Initial drug class:
ARBs: 4.2%
ACEi: 32.4%
CCBs: 14.9%
BBs: 34.1%
Diuretics: 14.4%
ARBs, Angiotensin receptor blockers; ACEi, Angiotensin converting enzyme inhibitor; CCBs, calcium channel blockers; BBs, Beta-blockers; y, years.
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(page number not for citation purposes)(10.3 [95%CI 9.9 to 10.8]) and a particularly strong
reduction of diastolic blood pressure with BBs (6.7 [95%
CI 6.2 to 7.1]). The average fall in blood pressure across
the five categories was 9.1 mmHg systolic and 5.5 mmHg
diastolic. Within each class there was no evidence that
any specific drug was substantially better than the others.
ARBs on average provided a better blood pressure
r e d u c t i o nt h a nA C E i( n e td i f f e r e n c e1 . 8 / 1 . 0m m H g ) ,
which could translate into a reduction in morbidity and
mortality [10].
Law et al. also investigated the reported adverse events from
these studies in their meta-analysis (Table 3). Symptoms
attributable to thiazides, BBs, and CCBs were strongly dose
related;symptomscausedbyACEi(mainlycough)werenot
dose related. ARBs caused no excess of symptoms.
Real-life data support the key findings of this meta-
analysis. The UK THIN general practice database with
16,866 records of patients receiving ACEi (14,651 pts) or
ARBs (2,215 pts) was analysed for example for the degree
of blood pressure reduction [11-14]. At one year, mean
systolic blood pressure reductions for patients receiving
A R B sr e a c h e d1 3 . 2m m H gc o m p a r e dt o1 1 . 1m m H gf o r
patients receiving ACEi (diastolic 7.8 vs. 6.7 mmHg).
Similar results were also observed after total treatment
duration of 2 years. The comparisons were significant
(p < 0.001) in a linear mixed multivariate model
adjusting for a number of confounding factors.
Studies on persistence with treatment
Table 4 displays the persistence with initial treatment in
8 studies ranging from 1 to 4 years of observation. In
most cases the persistence with ARBs was highest, with
12 month values of between 42 and 64%.
Table 3: Adverse effects of drugs: percentage of people with one or more symptoms attributable to treatment*, according to category
of drug and dose, in randomised trials [9, 20]
Percent (95%CI) with symptoms (treated minus placebo)
†
Drug class No. of trials 1/2 standard dose Standard dose Twice standard dose
Thiazides 59 2.0 [-2.2 to 6.3] 9.9 [6.6 to 13.2] 17.8 [11.5 to 24.2]
BBs 62 5.5 [0.3 to 10.7] 7.5 [4.0 to 10.9] 9.4 [3.6 to 15.2]
ACEi 96 3.9 [-3.7 to 11.6] 3.9 [-0.5 to 8.3] 3.9 [-0.2 to 8.0]
ARBs 44 -1.8 [-10.2 to 6.5] 0 [-5.4 to 5.4] 1.9 [-5.6 to 9.3]
CCBs 96 1.6 [-3.5 to 6.7] 8.3 [4.8 to 11.8] 14.9 [9.8 to 20.1]
ACE = angiotensin converting enzyme. *Calculated as difference between treated and placebo groups in proportion of participants who developed
one or more symptoms, excluding headaches, which were significantly less common in people receiving treatment.
†Commonest symptoms:
thiazides–dizziness, impotence, nausea, muscle cramp; Beta-blockers–cold extremities, fatigue, nausea; ACE inhibitors–cough; calcium channel
blockers–flushing, ankle oedema, dizziness.
Table 4: Persistence with initial treatment in different studies
Duration ARBs ACEi CCBs BBs Diuretics
Bloom [15] 12 64% 58%*** 50% 43% 38%
Conlin [18] 48 50.9% 46.5% 40.7%** 34.7%** 16.4%**
Hasford [36] 12 51.3% 42.0% 43.6% 49.7% 34.4%
Degli-Esposti [23] 12 41.7% 32.2% 26.7% 36.9% 25.9%
Erkens [37] 12 62.0% 59.7% 34.7% 35.0% 33.0%
Veronesi [19] 24 68.5% 64.5% 51.6%** 44.8%** 34.4%*
Hasford [17] 12 26.4% 28.2% 25.9% 25.8% 21.9%
Patel [16] 12 51.9% 48.0% 38.3% 40.3% 29.9%
Duration is given in month. *p < 0.01; **p < 0.05; *** p < 0.007 vs. ACEi.
Table 2: Averagereductioninbloodpressureover24hours(treated
minus placebo) according to category of drug and dose [9]
Drugs Systolic/Diastolic Fall in blood
pressure
(mmHg (95%CI))
Thiazides Systolic 8.8 (8.3 to 9.4)
Diastolic 4.4 (4.0 to 4.8)
Beta-blockers Systolic 9.2 (8.6 to 9.9)
Diastolic 6.7 (6.2 to 7.1)
ACE inhibitors Systolic 8.5 (7.9 to 9.0)
Diastolic 4.7 (4.4 to 5.0)
Angiotensin II receptor
antagonists
Systolic 10.3 (9.9 to 10.8)
Diastolic 5.7 (5.4 to 9.0)
Calcium channel blockers Systolic 8.8 (8.3 to 9.2)
Diastolic 5.9 (5.6 to 6.2)
In each category, the fall in blood pressure was standardised to the
average starting blood pressure across all trials of 154 mmHg systolic
and 97 mmHg diastolic; the estimates are the average over 24 hours
from combining separate peak and trough estimates.
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(page number not for citation purposes)ThestudybyBloometal.[15]reportedalowerpersistencewith
ACEi (OR 0.81; 95%CI 0.68–0.97), CCBs (OR 0.62 [95%CI
0.51–0.74]),BBs(OR0.56[95%CI0.47–0.68])andthiazides
(OR 0.36 [95%CI 0.30–0.43]) than with ARBs (reference)
over a 1 year period. Higher age (≥ 65 years) and once daily
dosing were also identified to increase persistence vs. young
ageormultipledosing.Conlinetal.reportedthe4yearfollow-
up of this cohort, which essentially resulted in compatible
results, although persistence rates further dropped over the
4 year follow-up. At 4 years ARBs had the highest persistence
with 50.9% of patients still being on monotherapy with a
stepwise decline for the other drug classes. A further study by
VeronesireportedthatthepersistencewithARBswasgenerally
high (68.5%) while ACEi (OR 0.94; 95%CI: 0.79–0.99),
CCBs (OR 0.76; 95%CI: 0.54–0.85), BBs (OR 0.67; 95%CI
0.57–0.79) and thiazide diuretics (OR 0.56; 95%CI 0.38–
0.84) had a lower persistence.
A study by Patel et al. reported, in addition to persistence
rates, a survivor function estimate (time to therapy
discontinuation) which is depicted in Figure 1[16]. Most
patientswhodiscontinued therapydidsowithinthe first 30
days of starting therapy. The differences between index drug
classes observed at 12 months post-index date were largely
evident at 1 month post-index date. Compared with
patients receiving diuretics, those receiving ARBs (HR
0.593; p < 0.0001), ACEi (HR 0.640; p < 0.0001), CCBs
(HR 0.859; p < 0.0001), and BBs (HR 0.819; p < 0.0001)
were all less likely to discontinue therapy.
One study however reported generally lower persistence
rates for all drug classes [17]. The persistence with ARBs
in this study was 26.4%, thus being lower than those of
ACEi with 28.2%.
Overall, patients on ARBs were more compliant than
patients on ACEi and CCBs, BBs and diuretics.
Blood pressure × persistence product
The blood pressure × persistence product could provide a
more meaningful insight into the true antihypertensive
effectiveness of antihypertensive drugs. Two approaches
were chosen to illustrate differences in the blood
pressure × persistence product:
1.) Placebo corrected blood pressure reductions reported in
the meta-analysis of Law et al. [9] were multiplied with the
persistence pattern at 1 year reported by Conlin et al. [18]
(Figure 2). The results show that ARBs, although having only
slightadvantagesinsystolic(butnotdiastolic)bloodpressure
reduction, resulted in the longest persistence with treatment
over a period of 4 years. Persistence and blood pressure
reduction with diuretics were on the other hand low as
compared to the other drug classes. The strengths of this
approach are that placebo corrected blood pressure reduc-
tions have been used from a large number of placebo
controlledtrials.Bloodpressurereductionswerebasedonthe
usual maintenance dose of drugs. The median treatment
durationofalltrialsinthisanalysiswashoweveronly4weeks
Figure 1
Time to therapy discontinuation of antihypertensive
monotherapy [16]. This depicts the proportion of study
patients by antihypertensive medication class who remained
persistentwithindextherapy(yaxis)duringtheyearsubsequent
totheindexstudyclaim(dayssubsequenttoindexdatedepicted
on x axis). ARB patients were most likely to remain on therapy,
closely followed by ACEi patients. Diuretic patients were least
likely to remain on the index monotherapy regimen.
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Figure 2
Blood pressure reduction vs. 4 year persistence with
treatment. Mean systolic blood pressure reduction was
taken from Law [9], 4 year persistence with monotherapy
was taken from Conlin [18].
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(page number not for citation purposes)which might result in an underestimation of true antihyper-
tensiveefficacyespeciallyfordrugswithaslowonsetofaction.
Further studies were included from a large time range, thus
giving rise to the notion that effects and treatment schemes
might be not comparable to the situation today.
2.) The study by Veronesi et al. [19] not only provided
persistence with treatment but also the blood pressure
lowering effect over a time frame of 2 years (Figure 3) from
the very same patients. For this reason many of the
limitations of the first approach do not apply. Compared
to the aforementioned version differences in the blood
pressureloweringeffect betweendrug classes are substantial
(within a range of -2.3 to -11.2 mmHg systolic and -2.1 to
-5.8 diastolic). Patients treated with ARBs had the most
effective blood pressure lowering (-11.2/-5.8 mmHg),
followed by ACE inhibitors (-10.5/-5.1 mmHg). Both
were significantly more effective than BB and diuretics
(p < 0.05) but not vs. each other. The variability in
persistence over 2 years is similar to the analysis above so
that larger differences between drug classes are evident.
However, the study did not record the dose used to achieve
the antihypertensive effect, which may confound the results
towards drugs used in higher doses. On the other hand
drugs with a good tolerability in high doses (as has been
reported for ACEi and ARBs by Law [20]) might result in
greater blood pressure reduction achievable in line with a
higher persistence.
Costs and cost-effectiveness
14 studies were identified that analysed the effect of
compliance and/or persistence on the cost or cost-
effectiveness of a treatment for hypertension.
Drug costs
Three studies investigated the drug costs with different
compliance and persistence in antihypertensive drug
treatment [21-23]. The early study by Degli-Eposti
reported mean drug costs to be highest for patients
adding another drug to their therapeutic regimen
(combination therapy, 274.69 €) and lowest for occa-
sional users (32.80 €) [21]. Patients who stayed on
therapy were less costly (121.51 €) than those switching
to another treatment (182.25 €).
In the 2004 study by Degli-Esposti [23], average drug
costs were found to be lowest for patients on diuretics
and those who discontinued therapy. Drug costs were
highest for patients being treated and being persistent
with ARB therapy (326.16 €), closely followed by
patients persistent with CCB treatment (234.63 €)a n d
patients switching between classes (up to 268.07 €).
Details can be found in Table 5.
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Figure 3
Blood pressure reduction vs. 2 year persistence with
treatment. Mean blood pressure reduction and persistence
with treatment over 2 years was taken from Veronesi [19].
Table 5: Annual average drug costs per patient for different antihypertensives according to the pattern of persistence [23]
Antihypertensive Continuers
[95%CI]
Switchers
[95%CI]
Discontinuers
95%CI]
Total
[95%CI]
Diuretics € 65.09
[58.67–71.52]
€ 153.10
[137.59–168.62]
€ 8.17
[7.60–8.75]
€ 33.45
[30.97–35.93]
Beta-blockers € 109.29
[102.46–116.12]
€ 158.73
[139.61–177.84]
€ 22.52
[24.24-23.79]
€ 63.40
[59.94–66.86]
Calcium-channel blockers € 234.63
[224.78–244.47]
€ 199.62
[183.45–215.78]
€ 38.24
[36.78–39.70]
€ 104.43
[100.07–108.79]
ACE inhibitors € 196.28
[189.69–202.86]
€ 237.53
[222.28–252.79]
€ 34.76
[33.53–35.99]
€ 108.25
[104.43–112.09]
Angiotensin II antagonists € 326.16
[313.05–339.27]
€ 268.07
[241.55–294.39]
€ 67.10
[62.89–71.31]
€ 201.53
[191.24–211.81]
Total € 171.73
[167.43–176.04]
€ 205.10
[196.85–213.34]
€ 28.29
[27.62–28.97]
€ 88.09
[86.10–90.08]
CI, confidence interval.
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When other, non-drug direct costs are taken into
account, the results are different. The impact of medica-
tion adherence on healthcare utilization and cost for 4
chronic conditions including hypertension was investi-
gated in a retrospective cohort study in patients who
were enrolled in a medical and prescription benefits plan
[24]. Patients were identified for disease-specific analyses
based on claims for outpatient, emergency room, or
inpatient services during the first 12 months of the study.
Using an integrated analysis of administrative claims
data, medical and drug utilization were measured during
the 12-month period after patient identification. Medi-
cation persistence was defined by days' supply of
maintenance medications for each condition. All-cause
costs were defined as any healthcare costs over a 1-year
period. For these, 80–100% persistence with treatment
for hypertension was associated with significantly lower
non-drug medical costs than for levels below 80% (6570
$ vs. 7658–10,286$; p < 0.05 for high vs. lower levels of
compliance) (Table 6). Therefore higher levels of
persistence with treatment were associated with lower
overall healthcare costs, despite high drug costs. The
decrease in healthcare costs with increasing persistence
was attributed mainly to a decrease in the risk of
hospitalisation (Figure 4). Similar associations were seen
for disease related costs (Figure 5). Disease-related costs
were defined as those associated with the disease only. In
hypertension, a higher level of persistence was associated
with lower disease-related costs. Results were however
not statistically significant.
In a retrospective study of hypertensive patients [25], the
highest direct costs were produced by patients changing
their medication by switching or adding another anti-
hypertensive drug (2142$), followed by non-persistent
patients (735$, p = 0.05 vs. first group) and noncom-
pliant patients (694$, p = 0.01 vs. first group). The
lowest costs were seen with persistent patients (341$, p =
0.01 vs. first group). Similar relations although on a
higher total level were observed for patients with
Table 6: Disease-Related Healthcare Costs and Hospitalization Risk at Varying Levels of Medication Adherence [24]
Adherence Level N Medical Costs ($) Drug Costs ($) Total Costs ($) Hospitalization Risk (%)
1–19 350 4847 31 4878 28
20–39 344 5973 89 6062 24
40–59 562 5113 184 5297 24
60–79 921 4977 285 5262 20
80–100 5804 4383 489 4871 19
F = 46.44** F = 171.98** X2 (31 df) = 1256.3**
Adj. r
2 =0 . 1 3 A d j .r
2 = 0.37
CI, confidence interval; *Indicates that the outcome is significantly higher than the outcome for the 80–100% adherence group (P < 0.05). Differences
were tested for medical cost and hospitalization risk; ** p < 0.0001.
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Risk of hospitalisation (%) in relation to the level of
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diabetes, congestive heart failure and angina. Patients
with renal failure produced the highest cost with 3936$
in patients changing their medication and lowest costs in
persistent patients (2135$). However, the compliance/
persistence data were based on self-report, making them
prone to various kinds of bias.
In a UK study based on the MEDIPLUS data set, patients
switching medication were again found to produce the
highest drug costs (218£ vs. 192£ for continuers).
Hospital costs were higher in patients either switching
or discontinuing therapy (70£) as compared to persis-
tent patients (46£). Total costs for patients were lower
for continuers (280£) than for patients switching
medication (336£) [26].
Indirect costs
Only one study investigated both direct and indirect
costs [27]. Besides drug costs, this study examined
indirect costs in terms of days missed from work. The
aim was to calculate the overall cost effects of employer-
provided drug coverage and of an increase in compliance
to 100%. Over a 1-year period with average co-payments
of 63% in hypertension, employers acquired mean 22.28
$ (corresponding to about 17.58 € as of December 2008)
extra drug costs per employee.
Increased compliance resulted in 3.48–16.06 saved work
days per employee. Assuming an average wage of 9.32$
per hour and fringe benefits of 25%, the benefit from
avoiding missed work days was greater than the extra
drug costs paid by the employers, resulting in a
significant yearly net benefit to the employers (286
[high 366, low 205]$ per employee; Table 7). Assuming
that compliance can be increased to 100%, the yearly
saving in indirect costs would amount to 191$ per
employee. However, as this assumption is not realistic,
these savings can only be interpreted as upper limits of
the potential savings.
Factors influencing cost effectiveness
Mar and colleagues evaluated the different parameters
influencing the cost-effectiveness of antihypertensive
drugs in patients with stage I and II arterial hypertension
[28]. Direct non-medical costs and indirect costs were
incorporated into some of the scenarios in addition to
direct medical costs. The cost of an additional Quality
Adjusted Life Year (QALY) varied substantially from
34,516€ in 30-year-old women to 3,307€ in 80 year old
men. Treatment of arterial hypertension stage II showed
lower ratios (19,798€/QALY in 30-year-old women and
1,918€/QALYin 80-year-old persons. The cost-effective-
ness ratio decreased with increasing age and was less in
men than in women (Figure 6). The inclusion of travel
and productivity costs increased the cost-effectiveness
ratio by 30% in women and by 35% in men. Assuming a
linear relationship between compliance and efficacy, a
decrease in compliance of 50% resulted in an increase in
the incremental cost effectiveness ratio (ICER) of 30–
50%. Cost-effectiveness ratios for arterial hypertension
stage I vary from 645€/QALY in 80-year-old men for
diuretics to 47 325€/QALY in 30-year old women for
ACEi's. This increase was greater in older patients and
was greater in men than women.
Discussion
The mere consideration of the blood pressure lowering
effect for the evaluation of antihypertensive drugs falls
short if patients' compliance and persistence with
treatment are not considered. This is evident from
studies in which it was shown that control rates in
hypertension are low [29-31]. On the basis of popula-
tion studies across the world hypertension control rates
have been reported as low as 53.1% for the US, 41.0%
for Canada, 33.6% for Germany and 29.2% for the UK
[32], which illustrate that the high control rates reported
in randomized controlled trials do not always translate
into clinical practice [33, 34]. It is therefore particularly
dangerous to utilize the blood pressure reduction from
short term randomized trials to extrapolate to costs of
treatment. Current attempts to limit the access to newer
antihypertensive drug classes [35] have to fail in
Table 7: Benefits to the employer of employer-provided drug coverage and increasing compliance to 100% in hypertension treatment [27]
Compliance level Treatment effect (days saved) Employer costs Employer savings Net benefit
Average compliance (37% drug coverage)
High 4.35 39 $ 405 $ 366 $
Base 3.48 325 $ 286 $
Low 2.62 244 $ 205 $
Additional benefit if compliance increased to 100%
High 2.55 22 $ 238 $ 216 $
Base 2.05 191 $ 169 $
Low 1.54 143 $ 121 $
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persistence with treatment as well as non-drug costs of
non-persistent patients are not taken into account.
Since there are no studies specifically addressing all
aspects of antihypertensive treatment, it was therefore
our aim to provide a comprehensive overview of the
available data. Several key findings deserve mentioning:
￿ A comprehensive meta-analysis has shown differ-
ences in the antihypertensive efficacy between anti-
hypertensive drug classes, favouring ARBs over other
d r u gc l a s s e s( A R B s>B B s>C C B s=t h i a z i d e s>A C E i
for systolic blood pressure) [9];
￿ Persistence with treatment is highest with ARBs
(ARBs > ACEi > CCBs > BBs > diuretics) [15, 16, 18,
19, 23, 36, 37];
￿ Drug costs are however higher with ARBs than with
any other drug class [21-23];
￿ A high persistence with drug treatment as can be
observed with more recent antihypertensive drugs
(ARBs, ACEi and CCBs) results in an over-compensa-
tion of direct drug costs, leading to a substantial
decrease in direct and indirect costs, and may also
translate into a reduction of morbidity and mortality
[24-27, 38].
There are however some open questions for which there
is a weaker evidence base.
Comparison of ARBs and ACEi after ONTARGET
After publication of the ONTARGET results [39, 40] the
discussion of whether ARBs or ACEi are superior
antihypertensive drugs was halted for some, since both
treatment regimens proved to be equally effective on the
long term to reduce cardiovascular events in high risk
patients with or without diabetes. In terms of blood
pressure reduction the trial did not however provide
f u r t h e re v i d e n c es i n c eb l o o dp r e s s u r ea tb a s e l i n ew a sl o w
already (blood pressure at baseline 142/82 mmHg) and
only a subset of patients was hypertensive per common
definitions (69%). Blood pressure was reduced by only
6.4/4.3 mmHg in the ramipril group and only 7.4/5.0
mmHg in the telmisartan group (difference of 0.9/0.6
mmHg in favour of telmisartan). The trial may however
provide evidence that ARBs may not provide additional
benefit over ACEi in case the blood pressure is already
low in the above mentioned patient population.
Differences among antihypertensive drugs within a class?
In their meta-analysis of 354 placebo controlled trials,
Law et al. found, although there were nominal differ-
ences, no significant evidence for differences in the
antihypertensive effect of different drugs within one class
[9, 20]: "Within each category there was no evidence that any
specific drug was materially better than the others." Two
aspects have to be considered when comparing different
drugs within a class. 1) Defined daily doses (DDD) are
not equally efficient doses. They were defined for
statistical purposes on drug utilization only and repre-
sent the "assumed average maintenance dose per day for a
drug used for its main indication in adults." This was
illustrated in a study by Dominiak and colleagues who
were able to demonstrate that in many cases 2 DDDs
have to be prescribed to be equally effective to drugs
prescribed at the usual DDD (Table 8) [41, 42].
Comparisons based on these DDDs for ARBs have
shown that the ARB irbesartan at 150 mg for example
is more effective than losartan 50 mg [43, 44] and
valsartan 80 mg [45]. 2) As ARBs can be prescribed at
ultrahigh doses such as to achieve adequate organ
protection [46, 47] and because of high tolerability
[20], the maximum achievable blood pressure reduction
Figure 6
Cost-effectiveness ratios of treatment of
hypertension, by hypertension stage, sex and age.
QALY, quality adjusted life year [28]
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efficacy comparison. There are however no randomized
controlled studies to address this issue and indirect
comparisons from multiple trials are always limited by
differences in baseline blood pressure and patient
characteristics.
Value of fixed dose combinations?
The majority of patients with hypertension receive
combination antihypertensive therapy. Current guide-
lines of the ESH/ESC recommend combination treat-
ment for patients uncontrolled on monotherapy or in
patients with blood pressure values on presentation
exceeding 20/10 above the respective patient target [6].
Fixed-dose combination of different drugs may help to
increase patients' compliance and persistence in these
cases. In hypertension, such combinations have the
potential to improve disease control and avoid hyperten-
sion-associated morbidity, thus increasing effectiveness
and lowering non-drug medical costs [48]. But most
studies assessing fixed-dose combination did not assess
patients' compliance and persistence. However retro-
spective studies have shown that fixed-dose combination
can lead to better compliance and persistence. This, in
turn, leads to better health outcomes and fewer adverse
medical events [49]. A recent study by Dickson and
Plauschinat evaluated compliance with a treatment of
the fixed-dose combination amlodipine/benazepril vs.
free combination therapy in elderly Medicaid recipients
[50]. The fixed combination treatment was associated
with improved compliance and lower healthcare costs
(defined as both drug and non drug costs) compared
with a free combination.
Conclusion
To evaluate drugs for the treatment of hypertension
several key variables have to be considered. These
variables include the blood pressure lowering effect,
side effects, compliance and persistence with treatment,
as well as drug costs and direct and indirect costs of
medical healthcare. Given that the highest persistence
with treatment results in the lowest non-drug costs,
substantial cost savings and a reduction of morbidity
might be expected making these drugs an attractive
choice for long term treatment of hypertension.
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